Evidence map›Paper›PMID 35140461›Full record

ArticleInternational journal of nanomedicine2022

Silver Nanoparticles as Chlorhexidine and Metronidazole Drug Delivery Platforms: Their Potential Use in Treating Periodontitis.

Karol P Steckiewicz, Piotr Cieciórski, Ewelina Barcińska, Maciej Jaśkiewicz, Magdalena Narajczyk, Marta Bauer, Wojciech Kamysz, Elżbieta Megiel, Iwona Inkielewicz-Stepniak

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 58 citations in OpenAlex.

  1. Green-SynthesizedJournal of functional biomaterials · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Karol P SteckiewiczDepartment of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.ORCID 0000-0002-5353-9849
Piotr CieciórskiFaculty of Chemistry, University of Warsaw, Warsaw, Poland.ORCID 0000-0003-0507-1513
Ewelina BarcińskaDepartment of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
Maciej JaśkiewiczDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.ORCID 0000-0003-4797-2635
Magdalena NarajczykLaboratory of Electron Microscopy, Faculty of Biology, University of Gdansk, Gdansk, Poland.ORCID 0000-0001-9806-8844
Marta BauerDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.
Wojciech KamyszDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.ORCID 0000-0001-5335-3043
Elżbieta MegielFaculty of Chemistry, University of Warsaw, Warsaw, Poland.
Iwona Inkielewicz-StepniakDepartment of Pharmaceutical Pathophysiology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland.ORCID 0000-0003-1676-2723
Gdańsk Medical University · PLUniversity of Warsaw · PLUniversity of Gdańsk · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePeriodontal disease (PD), defined as oral inflammation caused by dental plaque, is an emerging problem. PD may lead to tooth loss, and treatment options are limited. In this study, we designed, synthesized, and characterized silver nanoparticles (AgNPs) conjugated with chlorhexidine (AgNPs-CHL) or metronidazole (AgNPs-PEG-MET) to determine whether they can be used to treat PDs. MATERIALS AND

methodsAgNPs were synthesized and characterized by transmission electron microscopy, UV-vis spectrometry, thermogravimetric analyses, and dynamic light scattering. We determined the safety and the antimicrobial and anti-inflammatory properties of synthesized AgNPs in an in vitro model of periodontitis. Antimicrobial properties were determined by measuring the minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) on reference strains of bacteria and fungi. Human gingival fibroblast (HGF-1), murine macrophage (RAW264.7) and human foetal osteoblast (hFOB1.19) cells were used in the study. Lipopolysaccharide (LPS) was used to induce inflammation. Cytokine levels were measured using an enzyme-linked immunosorbent assay; metalloproteinase expression was measured using Western blotting.

resultsThe synthesized AgNPs were spherical and narrow-dispersed with an average diameter of 13.4 nm ± 3.0 nm in the case of AgNPs-CHL and 3.72 nm ± 0.72 nm in the case of AgNPs-PEG-MET. Both types of AgNPs were active against bacteria and fungi. AgNPs-CHL proved to be a more potent antimicrobial agent, although they were more cytotoxic than AgNPs-PEG-MET; however, both demonstrated beneficial properties in nontoxic concentrations. AgNPs-CHL and AgNPs-PEG-MET decreased the production of proinflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. Both agents also decreased the levels of metalloproteinases MMP3 and MMP8, which may indicate that they will inhibit tissue degradation.

conclusionAgNPs-CHL and AgNPs-PEG-MET may be possible therapeutic options for PD, as they have antibacterial and anti-inflammatory properties. However, to fully understand the potential of AgNPs, our in vitro findings must be evaluated in an in vivo model.

Indexed as

Metal NanoparticlesPeriodontitisPharmaceutical PreparationsAnimalsChlorhexidineHumansMetronidazoleMiceSilverChlorhexidineMetronidazolePharmaceutical PreparationsSilverdrug delivery platformsgingival fibroblastmacrophagesosteoblastsperiodontal diseaseperiodontitis

Identifiers

PMID35140461
PMCPMC8820264
OpenAlexW4210415481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.